MedTrace Logo

PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine

NCT01441765 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2017-02-08

Study results available
· View outcomes & findings →

Summary

CT-011 is an investigational monoclonal antibody. Monoclonal antibodies are a type of drug that are known to target specific cells (in this case, cells in the immune system) The DC RCC Vaccine is agent that tries to help the immune system to recognize and fight against cancer cells.

The purpose of this research study is to determine the safety of CT-011 alone, and in combination with the Dendritic Cell Renal Cell Carcinoma (DC RCC) vaccine. The investigators are also trying to find out what effect the combination has on the disease, and on your immune system.

Conditions

Interventions

DRUG

CT-011

CT-011 at 3 mg/kg IV for 4 cycles of 6 weeks

BIOLOGICAL

DC/RCC fusion vaccine

Vaccination once per cycle on Day 8 of treatment cycles 2-4

Sponsors & Collaborators

Principal Investigators

  • David Avigan, MD · Beth Israel Deaconess Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01441765 on ClinicalTrials.gov